Thromboelastography Market Size to Exceed USD 1,199.3 Mn by 2032

The Thromboelastography Market, estimated at USD 742.0 Mn in 2025, is expected to exhibit a CAGR of 7.1% and reach USD 1,199.3 Mn by 2032.

The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.

Various research institutes and companies are engaged in conducting clinical trials to develop novel and efficient heparinase assays which is expected to drive the segment growth over the forecast period. For instance, in December 2025, Postgraduate Institute of Medical Education and Research completed a study to evaluate coagulation profile and role of endogenous heparinoids SONOCLOT (coagulation factor assays for VIII/X, XIII, TPA/ PAI) in acute variceal bleeding in cirrhosis. The study was performed in Postgraduate Institute of Medical Education and Research, Chandigarhs on the targeted subjects with age of 18 Years to 65 Years. 

Global Thromboelastography Market – Impact of Coronavirus (COVID-19) Pandemic

The most recent pandemic is the coronavirus (COVID-19) pandemic, which was initially detected on December 31, 2025, in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2025. According to the World Health Organization's Coronavirus Illness (COVID-19) Epidemiological Update, coronavirus disease (COVID-19) caused approximately 616.9 million cases and 6.53 million fatalities globally, till October 7, 2025.

For instance, on June 10, 2025, an article named Role of Thromboelastography and Thromboelastometry in predicting risk of hypercoagulability and thrombosis in critically ill COVID-19 patients - A Qualitative Systematic Review published in Turkish Journal of Anaesthesiology and Reanimation, declared that thromboelastography can help in understanding the mechanism, time course and prognostic value of coagulation disturbance in critically ill patients with COVID-19. Serial TEG/ROTEM over the course of illness may be more informative in guiding about the trend of coagulation disturbance.

Browse  40 Market Data Tables and 48 Figures spread through 197 Pages and in-depth TOC on “Global Thromboelastography Market”- Global Forecast to 2032, Global Pneumococcal Vaccines Market, by Type (Standard (kaolin), Rapid TEG, Native TEG,

Heparinase, Functional Fibrinogen, Platelet Mapping), by Application (Cardiopulmonary Bypass, Liver Surgery, Trauma surgery, Obstetrics), by End User (Hospitals, Blood Banks, Academic Institutes, Others (Research Laboratories, Research Institutes)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

https://www.coherentmarketinsights.com/market-insight/thromboelastography-machine-market-2371

Market players are focusing on various inorganic growth strategies such as acquisitions to strengthen their market presence, which is expected to boost the market growth in this region over the forecast period. For instance, in April 2025, Haemonetics Corporation, a global provider of blood and plasma supplies and services, announced the acquisition of Enicor GmbH, a manufacturer of whole blood coagulation testing system (ClotPro). Through this acquisition, Haemonetics Corporation will integrate the ClotPro analyzer technology with TEG 5000 Hemostasis Analyzer and TEG 6s Hemostasis Analyzer to provide its customers with a wide range of offerings.

Key Takeaways of the Global Pneumococcal Vaccines Market:

• Global thromboelastography market is expected to exhibit a CAGR of 7.1% during the forecast period owing to the product launches and approvals associated with thromboelastography by regulatory bodies. For instance, in May 2025, Haemonetics Corporation, a global provider of blood and plasma supplies and services, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the medical indication of its TEG 6s Hemostasis Analyzer System.
• Major players operating in the global thromboelastography market includes Lepu Medical Technology (Beijing) Co.,Ltd., Render Biotech Co., Haemonetics Corporation, TA Instruments, HemaCore LLC, 5-Diagnostics, Xenometrix AG, Framar Hemologix srl, Instrumentation Laboratory, Medirox AB, Diagnostica Stago, Life Diagnostica, SYCOmed e.K., Nordic Biomarker, and Shenzhen Ultra-Diagnostics Biotec. Co., Ltd.